Available Technological Offer
A new immunotherapy strategy based on the administration of a monoclonal antibody specific for pre-TCR has been developed and validated in a preclinical human T-ALL xenotransplantation model in mice.
A new immunotherapy strategy based on the administration of ADCs or CAR-T cells derived from a monoclonal antibody specific for the pre-TCR receptor, which impairs LIC activity and tumor progression, has been developed and validated in a preclinical human T-ALL xenotransplantation model in mice.
A panel of high affinity nanobodies (Nb) binding to diverse SARS-CoV-2 RBD epitopes of spike protein, and a set of nanobody-derived neutralizing heavy chain antibodies (hcAbs) have been identified. They have potential as therapy against SRAS-CoV-2 for immunocompromised or non-responding to vaccines individuals.